A next-generation positron emission tomography/computed tomography (PET/CT) system, Biograph Vision.X, reportedly offers enhanced spatial resolution and a time of flight of 178 picoseconds.
Biograph Vision.X (Image Credit: Seimens Healthineers)
Offering technological advancements ranging from an accelerated time of flight (TOF) to artificial intelligence (AI)-enabled workflow enhancements, Siemens Healthineers showcased Biograph Vision.X, a new positron emission tomography/computed tomography (PET/CT) system at the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place June 24-27 in Chicago.
One of the new system’s benefits is the Optiso Ultra Dynamic Range detector technology, which reportedly provides enhanced spatial resolution through silicon photomultipliers (SiPMs) that facilitate utilization of small (3.2 mm x 3.2 mm) lutetium oxyorthosilicate crystal elements.
Leveraging this technology, the Biograph Vision.X also offers a TOF of 178 picoseconds that bolsters patient throughput and reduces radiation exposure for patients, according to Siemens Healthineers.
“This TOF improvement translates into true increased sensitivity for better imaging performance. This level of precision is more important than ever as more physicians now use PET/CT imaging not only for diagnosis but throughout the patient care cycle – from diagnosis to therapy monitoring to post-therapy follow up,” noted James Williams, Ph.D, the head of Siemens Healthineers Molecular Imaging. “And such precision in PET/CT is invaluable in theranostics, where diagnostic and therapeutic capabilities are combined to help treat post-recurrent prostate cancer patients.”
The company added that the system leverages AIDAN intelligent imaging, an AI platform built on over 700 patented machine- and deep learning applications, to enhance radiology workflow efficiency.
Pending 510(k) clearance from the Food and Drug Administration, the Biograph Vision.X system is not commercially available at this time, according to Siemens Heathineers. The company said the new system will be available as in-field upgrade for physicians who currently utilize the Biograph Vision device.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).